Abstract:Abstract Microsatellite instability (MSI), a functional measure of mismatch repair (MMR) deficiency, and immunohistochemistry testing for MMR proteins are well established technologies traditionally used for Lynch Syndrome screening in colorectal cancer. Recently testing for MMR deficiency, by MSI analysis or MMR protein expression, has expanded from hereditary cancer risk testing to a new role predicting immunotherapeutic response in all solid tumors. With this increase in utility and awareness, mismatch repair deficiency is now relevant in a variety of other cancer tissue types. However, little data is available for the performance of these testing techniques in non-colorectal cancer samples. In this study, we examine performance of methods for detecting MSI and MMR protein expression in endometrial cancer samples. 200 endometrial cancer samples were obtained for testing with MSI by PCR followed by capillary electrophoresis, and immunohistochemistry for MMR protein expression. Instability at 2/5 microsatellite loci was used as criteria for MSI-H designation and loss of immunostaining for one or more MMR protein was considered dMMR. Performance of these analysis methods for identification of MMR protein mutations was measured by comparing results to sequencing of MMR proteins using NGS. MSI by PCR followed by capillary electrophoresis and immunohistochemistry for all four major MMR proteins was successfully performed on all (200/200) samples. 140/200 samples had matched adjacent tissue for reference when performing MSI analysis. MSI and MMR did not exhibit 100% concordance, as expected due to their measurement of different biological effects associated with MMR deficiency. We also describe instances of microsatellite loci exhibiting more subtle shifts than those commonly observed in colorectal cancer, especially at shorter nucleotide repeats, an important consideration for future studies with pan-tumor MSI testing. With the increasing utility of identifying mismatch repair defects in hereditary and immuno-oncology for pan-tumor applications, choosing a testing approach that has the highest sensitivity is key. Our findings suggest that for maximal identification of mismatch repair deficiency, MMR by IHC and MSI by PCR are complementary technologies and should not be considered interchangeable. Consistent with these findings, a number of guideline committees globally have begun recommending co-testing for MMR and MSI. These two cost effective tools can be used together for both a functional and informative approach prior to more costly downstream testing. Citation Format: Samantha R. Lewis, Kathryn Oostdik, Shaun Peterson, Heather Tomlinson. A performance characterization of microsatellite instability and mismatch repair testing methods in endometrial samples [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4251.

A Review on Immunohistochemistry Staining Patterns and Clinical Implications

Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer

Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway

The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations

Retrospective Analysis of the Correlation of MSI-H/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs

The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

A Prospective Study to Evaluate the Prevalence of Microsatellite Instability in Endometrial Carcinoma by using Immunohistochemistry for Mismatch Repair Proteins as a Surrogate Marker

Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma

A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas

Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer

Prognostic implications of immunohistochemistry in patients with endometrial cancer

A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair‐deficient and microsatellite instability‐high endometrial cancers

Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting

Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches

Abstract 4251: A performance characterization of microsatellite instability and mismatch repair testing methods in endometrial samples

The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions

Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology

Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy